Terms: = Sarcomas AND MYC, c-Myc, 4609, ENSG00000136997 AND Treatment
226 results:
1. Design, Synthesis, and Anti-Leukemic Evaluation of a Series of Dianilinopyrimidines by Regulating the Ras/Raf/MEK/ERK and STAT3/c-myc Pathways.
Wang C; Wang B; Mou Y; Liu X; Chen Q; Pu W; Rao Q; Wang C; Song J; Huang Y; Yan L; Huang L; Li Y
Molecules; 2024 Apr; 29(7):. PubMed ID: 38611876
[TBL] [Abstract] [Full Text] [Related]
2. Polyphyllin I enhances tumor necrosis factor-related apoptosis-inducing ligand-induced inhibition of human osteosarcoma cell growth downregulating the Wnt/β-catenin pathway.
Junli C; Fulai Z; Xingyuan S; Xiaoping MA; Peng Z; Chujie Z; Binhao S; Wenchao GU; Yongjun W; Yanping Y
J Tradit Chin Med; 2024 Apr; 44(2):251-259. PubMed ID: 38504531
[TBL] [Abstract] [Full Text] [Related]
3. Screening for Synergistic Reagents With Pazopanib Against Osteosarcoma Using a Compound Library.
Yada Y; Asanuma K; Kakimto T; Okuno K; Okamoto T; Iino T; Nakamura T; Sudo A
Anticancer Res; 2024 Mar; 44(3):1071-1078. PubMed ID: 38423639
[TBL] [Abstract] [Full Text] [Related]
4. Identifying squalene epoxidase as a metabolic vulnerability in high-risk osteosarcoma using an artificial intelligence-derived prognostic index.
Wang Y; Ma X; Xu E; Huang Z; Yang C; Zhu K; Dong Y; Zhang C
Clin Transl Med; 2024 Feb; 14(2):e1586. PubMed ID: 38372422
[TBL] [Abstract] [Full Text] [Related]
5. Up-regulation of RAN by MYBL2 maintains osteosarcoma cancer stem-like cells population during heterogeneous tumor generation.
Gao W; Zhou J; Huang J; Zhang Z; Chen W; Zhang R; Kang T; Liao D; Zhong L
Cancer Lett; 2024 Apr; 586():216708. PubMed ID: 38336287
[TBL] [Abstract] [Full Text] [Related]
6. Unraveling T cell exhaustion in the immune microenvironment of osteosarcoma via single-cell RNA transcriptome.
Cheng D; Zhang Z; Liu D; Mi Z; Tao W; Fu J; Fan H
Cancer Immunol Immunother; 2024 Jan; 73(2):35. PubMed ID: 38280005
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic characteristics of a six-gene signature based on ssGSEA in sarcoma.
Liu J; Lu J; Wang G; Gu L; Li W
Aging (Albany NY); 2024 Jan; 16(2):1536-1554. PubMed ID: 38240704
[TBL] [Abstract] [Full Text] [Related]
8. m
Zhang D; Guo Q; You K; Zhang Y; Zheng Y; Wei T
J Orthop Surg Res; 2024 Jan; 19(1):33. PubMed ID: 38178201
[TBL] [Abstract] [Full Text] [Related]
9. Identification and experimental validation of Stearoyl-CoA desaturase is a new drug therapeutic target for osteosarcoma.
Nie J; He C; Shu Z; Liu N; Zhong Y; Long X; Liu J; Yang F; Liu Z; Huang P
Eur J Pharmacol; 2024 Jan; 963():176249. PubMed ID: 38070637
[TBL] [Abstract] [Full Text] [Related]
10. Genomic and Molecular Characteristics of Ovarian Carcinosarcoma.
Ramphal K; Hadfield MJ; Bandera CM; Hart J; Dizon DS
Am J Clin Oncol; 2023 Dec; 46(12):572-576. PubMed ID: 37986208
[TBL] [Abstract] [Full Text] [Related]
11. Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma.
Kinnaman MD; Zaccaria S; Makohon-Moore A; Arnold B; Levine MF; Gundem G; Arango Ossa JE; Glodzik D; Rodríguez-Sánchez MI; Bouvier N; Li S; Stockfisch E; Dunigan M; Cobbs C; Bhanot UK; You D; Mullen K; Melchor JP; Ortiz MV; O'Donohue TJ; Slotkin EK; Wexler LH; Dela Cruz FS; Hameed MR; Glade Bender JL; Tap WD; Meyers PA; Papaemmanuil E; Kung AL; Iacobuzio-Donahue CA
Cancer Res; 2023 Nov; 83(22):3796-3812. PubMed ID: 37812025
[TBL] [Abstract] [Full Text] [Related]
12. Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer.
Shin DH; Jo JY; Choi M; Kim KH; Bae YK; Kim SS
Exp Mol Med; 2023 Oct; 55(10):2220-2237. PubMed ID: 37779142
[TBL] [Abstract] [Full Text] [Related]
13. Network Pharmacology-Based Identification of Key Pharmacological Mechanism of Shen-qi-di-huang Decoction Acting on Uremia.
Zhang X; Chen XF; Chen WJ; Ding H; Zhang BX
Altern Ther Health Med; 2024 Jan; 30(1):44-50. PubMed ID: 37773677
[TBL] [Abstract] [Full Text] [Related]
14. RHAMM/hyaluronan inhibit β-catenin degradation, enhance downstream signaling, and facilitate fibrosarcoma cell growth.
Berdiaki A; Thrapsanioti LN; Giatagana EM; K Karamanos N; C Savani R; N Tzanakakis G; Nikitovic D
Mol Biol Rep; 2023 Nov; 50(11):8937-8947. PubMed ID: 37710072
[TBL] [Abstract] [Full Text] [Related]
15. The Targeted Therapies for Osteosarcoma
Wang S; Ren Q; Li G; Zhao X; Zhao X; Zhang Z
Curr Mol Pharmacol; 2024; 17(1):e210823220109. PubMed ID: 37602543
[TBL] [Abstract] [Full Text] [Related]
16. Deciphering the Signaling Mechanisms of Osteosarcoma Tumorigenesis.
Nirala BK; Yamamichi T; Yustein JT
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511127
[TBL] [Abstract] [Full Text] [Related]
17. Dysregulation of iron homeostasis by TfR-1 renders EZH2 wild type diffuse large B-cell lymphoma resistance to EZH2 inhibition.
Yu L; Wang YF; Xiao J; Shen QQ; Chi SS; Gao YL; Lin DZ; Ding J; Fang YF; Chen Y
Acta Pharmacol Sin; 2023 Oct; 44(10):2113-2124. PubMed ID: 37225847
[TBL] [Abstract] [Full Text] [Related]
18. The Functional Role and Regulatory Mechanism of FTO m
Yang Q; Al-Hendy A
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175660
[TBL] [Abstract] [Full Text] [Related]
19. Echinomycin as a promising therapeutic agent against KSHV-related malignancies.
Chen J; Lin Z; Song J; Plaisance-Bonstaff K; James J; Mu S; Post SR; Dai L; Qin Z
J Hematol Oncol; 2023 May; 16(1):48. PubMed ID: 37143124
[TBL] [Abstract] [Full Text] [Related]
20. Clinical Targeted Next-Generation Panel Sequencing Reveals
Marinoff AE; Spurr LF; Fong C; Li YY; Forrest SJ; Ward A; Doan D; Corson L; Mauguen A; Pinto N; Maese L; Colace S; Macy ME; Kim A; Sabnis AJ; Applebaum MA; Laetsch TW; Glade-Bender J; Weiser DA; Anderson M; Crompton BD; Meyers P; Zehir A; MacConaill L; Lindeman N; Nowak JA; Ladanyi M; Church AJ; Cherniack AD; Shukla N; Janeway KA
JCO Precis Oncol; 2023 Mar; 7():e2200334. PubMed ID: 36996377
[TBL] [Abstract] [Full Text] [Related]
[Next]
